Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
20 11월 2009 - 9:00PM
PR Newswire (US)
"Fracture putty" system to improve standard of care for injured
soldiers MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCall/ -- Smith
& Nephew (NYSE: SNNNYSE:LSE:NYSE:SN) Orthopaedics Division is
pleased to announce the signing of a technology development
contract with the United States Department of Defense that may lead
to the creation of a fracture fixation system intended to
revolutionize the treatment of the limbs of soldiers who sustain
battlefield injuries. Last year, the Defense Advanced Research
Projects Agency (DARPA), the central research and development
agency for the U.S. Department of Defense, accepted proposals to
create and develop "fracture putty," a dynamic new material that
would markedly enhance the healing of soldiers who suffer traumatic
wounds in the field of battle. These wounds often lead to secondary
fractures and infections, multiple surgeries, long rehabilitation
times and, in some cases, amputation. In particular, injuries
sustained from improvised explosive devices (IEDs) are difficult to
treat due to the usually significant loss of bone and soft tissue.
The fracture putty system is intended to provide substantial
support of the injured limb early in the body's natural healing
process so the soldier can more quickly participate in physical
therapy and thus reduce the risk of further complications. The
putty will then resorb - meaning it will dissolve over time,
leaving natural healthy bone in its place. Today's standard
treatment methods include permanent metal support devices such as
plates, rods and bone screws. Smith & Nephew is the only
medical device company chosen to work on this futuristic material.
Beyond this initial project, the company may expand the application
of the technology to the treatment of other kinds of bone fractures
in both military and civilian trauma care. "Fracture putty
represents the ultimate convergence of orthopaedic material science
and mechanics, and has the potential to revolutionize the way
patients are treated," said DARPA's program manager, Mitchell
Zakin, PhD. "If all technical challenges are met, we believe this
innovative technology will provide superior clinical outcomes for
patients." "This announcement represents the spirit of innovation
that drives Smith & Nephew scientists and engineers," said
David Brumfield, vice president of product development in Smith
& Nephew Orthopaedics' Trauma franchise. "We will use the full
extent of our expertise, ground-breaking material technology and
quality manufacturing to create the best possible treatment for
those who have been injured while serving our country." Smith &
Nephew's history of orthopaedic trauma innovation includes the
introduction of the compression hip screw and intramedullary hip
fracture fixation. Additionally, Smith & Nephew was responsible
for introducing the ILIZAROV(TM) method of external circular
fixation to the United States, which is manifested today in its
award winning TAYLOR SPATIAL FRAME(TM) device, a technology
currently used to treat complex fractures sustained by US military
personal. About us Smith & Nephew is a global medical
technology business, specialising in Orthopaedics, including
Reconstruction, Trauma and Clinical Therapies; Endoscopy and
Advanced Wound Management. Smith & Nephew is a global leader in
arthroscopy and advanced wound management and is one of the leading
global orthopaedics companies. Smith & Nephew is dedicated to
helping improve people's lives. The Company prides itself on the
strength of its relationships with its surgeons and professional
healthcare customers, with whom its name is synonymous with high
standards of performance, innovation and trust. The Company
operates in 32 countries around the world. Annual sales in 2008
were $3.8 billion. About DARPA DARPA is the central research and
development organization for the U.S. Department of Defense (DoD).
It manages and directs selected basic and applied research and
development projects for DoD, and pursues research and technology
where risk and payoff are both very high and where success may
provide dramatic advances for traditional military roles and
missions. Forward-Looking Statements This press release contains
certain "forward-looking statements" within the meaning of the US
Private Securities Litigation Reform Act of 1995. In particular,
statements regarding planned growth in our business and in our
trading margins discussed under "Outlook" are forward-looking
statements as are discussions of our product pipeline. These
statements, as well as the phrases "aim", "plan", "intend",
"anticipate", "well-placed", "believe", "estimate", "expect",
"target", "consider" and similar expressions, are generally
intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors (including, but not
limited to, the outcome of litigation and regulatory approvals)
that could cause the actual results, performance or achievements of
Smith & Nephew, or industry results, to differ materially from
any future results, performance or achievements expressed or
implied by such forward-looking statements. Please refer to the
documents that Smith & Nephew has filed with the U.S.
Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith & Nephew's
most recent annual report on Form 20F, for a discussion of certain
of these factors. All forward-looking statements in this press
release are based on information available to Smith & Nephew as
of the date hereof. All written or oral forward-looking statements
attributable to Smith & Nephew or any person acting on behalf
of Smith & Nephew are expressly qualified in their entirety by
the foregoing. Smith & Nephew does not undertake any obligation
to update or revise any forward-looking statement contained herein
to reflect any change in Smith & Nephew's expectation with
regard thereto or any change in events, conditions or circumstances
on which any such statement is based. DATASOURCE: Smith &
Nephew CONTACT: Analyst/Investor Inquiries: Liz Hewitt, Smith &
Nephew, +44 (0) 20 7401 7646; or Media Inquiries: Andrew Burns,
Smith & Nephew, +1-901-399-5739, Web Site:
http://www.smith-nephew.com/
Copyright